DDInter1397 DDInter465
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model, although further investigations are needed.
Paroxetine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dacomitinib
Paroxetine {u} (Compound) binds {v} (Gene) HTR2A
HTR2A {u} (Gene) is bound by {v} (Compound) Risperidone
Risperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Paroxetine {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is upregulated by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dacomitinib
Paroxetine {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is downregulated by {v} (Compound) Maprotiline
Maprotiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Paroxetine {u} (Compound) upregulates {v} (Gene) TSC22D3
TSC22D3 {u} (Gene) is upregulated by {v} (Compound) Perphenazine
Perphenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Paroxetine {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is upregulated by {v} (Compound) Thioridazine
Thioridazine {u} may lead to a major life threatening interaction when taken with {v} Dacomitinib
Paroxetine {u} (Compound) downregulates {v} (Gene) CCNB2
CCNB2 {u} (Gene) is downregulated by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dacomitinib
Paroxetine {u} (Compound) downregulates {v} (Gene) CCNB2
CCNB2 {u} (Gene) is downregulated by {v} (Compound) Famotidine
Famotidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Paroxetine {u} (Compound) downregulates {v} (Gene) CCNB2
CCNB2 {u} (Gene) is downregulated by {v} (Compound) Pimozide
Pimozide {u} may lead to a major life threatening interaction when taken with {v} Dacomitinib
Paroxetine {u} (Compound) causes {v} (Side Effect) Eosinophilia
Eosinophilia {u} (Side Effect) is caused by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dacomitinib
Paroxetine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dacomitinib
Paroxetine (Compound) binds HTR2A (Gene) and HTR2A (Gene) is bound by Risperidone (Compound) and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Paroxetine (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dacomitinib
Paroxetine (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is downregulated by Maprotiline (Compound) and Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Paroxetine (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Perphenazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Paroxetine (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Thioridazine (Compound) and Thioridazine may lead to a major life threatening interaction when taken with Dacomitinib
Paroxetine (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is downregulated by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dacomitinib
Paroxetine (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is downregulated by Famotidine (Compound) and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Paroxetine (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is downregulated by Pimozide (Compound) and Pimozide may lead to a major life threatening interaction when taken with Dacomitinib
Paroxetine (Compound) causes Eosinophilia (Side Effect) and Eosinophilia (Side Effect) is caused by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dacomitinib